

Communicable Disease Reporting in Montana

Suspected or confirmed cases of the following diseases must be reported to your <u>local health department</u>, per <u>ARM 37.114.201</u>. Additionally reportable is any unusual incident or unexplained illness or death in a human or animal with potential human health implications, per <u>ARM 37.114.203</u>.

If your Local Public Health Jurisdiction is unavailable, call 406-444-0273 (available 24/7)

Acquired Immune Deficiency Syndrome (AIDS)

Anaplasmosis

Anthrax⁽¹⁾

Arboviral diseases, neuroinvasive and non-neuroinvasive (California serogroup, Chikungunya, Eastern equine encephalitis, Powassan, St. Louis encephalitis, West Nile virus, Western equine encephalitis, Zika virus infection)

Arsenic poisoning (urine levels ≥70 micrograms/liter total arsenic ≥35 micrograms/liter methylated plus inorganic arsenic)

Babesiosis

Botulism (infant, foodborne, other, and wound) (1)

Brucellosis (1)

Cadmium poisoning (blood level ≥5 micrograms/liter or

urine level ≥3 micrograms/liter)

Campylobacteriosis Candida auris¹ Chancroid

Chlamydia trachomatis infection

Coccidioidomycosis Colorado tick fever

Coronavirus Disease 2019 (COVID-19)

Cryptosporidiosis Cyclosporiasis

Dengue virus infection

Diphtheria⁽¹⁾ Ehrlichiosis

Escherichia coli, Shiga-toxin producing (STEC) 1

Gastroenteritis outbreak

Giardiasis

Gonorrheal infection Granuloma inguinale

Haemophilus influenzae, invasive disease 1

Hansen's disease (leprosy)

Hantavirus Pulmonary Syndrome/infection^① Hemolytic Uremic Syndrome, post-diarrheal

Hepatitis A, acute

Hepatitis B, acute, chronic, perinatal Hepatitis C, acute, chronic, perinatal Human Immunodeficiency Virus (HIV)

Influenza (including hospitalizations and deaths)
Lead levels in a venous blood specimen at any level

Lead levels in a capillary blood specimen ≥3.5 micrograms per

deciliter in a person less than 16 years of age

Legionellosis Leptospirosis Listeriosis¹ Lyme disease

Lymphogranuloma venereum

Malaria

Measles (rubeola) 1

Melioidosis¹

Meningococcal disease (Neisseria meningitidis) ①

Mercury poisoning (urine level ≥10 micrograms/liter or urine level ≥10 micrograms/liter elemental mercury/gram of creatinine or blood level ≥10 micrograms/liter elemental, organic, and inorganic mercury

Monkeypox Mumps Pertussis

Plague (Yersinia pestis) 1

Poliomyelitis¹
Psittacosis

Q Fever (Coxiella burnetii), acute and chronic

Rabies, human and animal

(Including exposure to a human by a species

susceptible to rabies infection)
Rubella, including congenital^①

Salmonellosis (including Salmonella typhi and

paratyphi⁽¹⁾

Severe Acute Respiratory Syndrome-associated

Coronavirus (SARS-CoV) disease (1)

Shigellosis¹ Smallpox¹

Spotted fever rickettsiosis

Streptococcus pneumoniae, invasive disease Streptococcal toxic shock syndrome (STSS)

Syphilis Tetanus

Tickborne relapsing fever

Toxic shock syndrome, non-streptococcal (TSS) Transmissible spongiform encephalopathies (including Creutzfeldt Jakob Disease)

Trichinellosis (Trichinosis) 1

Tuberculosis (including latent tuberculosis infection)

Tularemia¹

Varicella (chickenpox)

Vibrio cholerae infection (Cholera) 1

Vibriosis⁽¹⁾

Viral hemorrhagic fevers

Yellow fever

Outbreak in an institutional or congregate setting

Additional Laboratory Requirements for submission of Selected Specimens/Reports:

1 a specimen must be sent to the Montana Public Health Laboratory for confirmation, per <u>ARM 37.114.313</u>. Additional specimens may be requested by CDEpi. For additional information, contact the <u>Montana Public Health Laboratory at 1-800-821-7284</u>.

Isolates: In addition to selected conditions noted above, suspected or confirmed isolates of Multidrug-Resistant Organisms (MDRO) of significance, including Carbapenem resistant organisms (CRO), Vancomycin-intermediate or resistant *Staphylococcus aureus* (VISA or VRSA) must be sent to MTPHL for confirmation, when possible.

Influenza specimens may be requested for confirmation of severe presentations/mortality and outbreaks, or subtyping for surveillance purposes. In addition, suspected novel influenza strains are required to be submitted for confirmation and additional testing by CDC.